Zimmer Biomet’s (ZBH) “Hold” Rating Reiterated at Needham & Company LLC

Needham & Company LLC restated their hold rating on shares of Zimmer Biomet (NYSE:ZBH) in a report published on Friday morning,Benzinga reports.

Other equities analysts have also recently issued reports about the stock. Truist Financial boosted their target price on shares of Zimmer Biomet from $117.00 to $118.00 and gave the company a “hold” rating in a research note on Wednesday, December 18th. Stifel Nicolaus upped their price objective on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a research report on Thursday, January 23rd. Wells Fargo & Company raised their target price on Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. JPMorgan Chase & Co. raised Zimmer Biomet from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $125.00 to $128.00 in a report on Tuesday, December 17th. Finally, Oppenheimer dropped their price objective on Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating on the stock in a report on Tuesday, October 15th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $124.70.

Zimmer Biomet Trading Down 1.6 %

Shares of Zimmer Biomet stock opened at $101.01 on Friday. Zimmer Biomet has a 12-month low of $99.93 and a 12-month high of $133.90. The firm’s 50 day simple moving average is $107.34 and its two-hundred day simple moving average is $108.08. The company has a current ratio of 1.91, a quick ratio of 0.70 and a debt-to-equity ratio of 0.43. The firm has a market capitalization of $20.11 billion, a price-to-earnings ratio of 22.70, a PEG ratio of 1.83 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the previous year, the business earned $2.20 earnings per share. Analysts predict that Zimmer Biomet will post 8.25 EPS for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Monday, December 30th were issued a dividend of $0.24 per share. The ex-dividend date of this dividend was Monday, December 30th. This represents a $0.96 dividend on an annualized basis and a yield of 0.95%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 21.57%.

Institutional Investors Weigh In On Zimmer Biomet

Hedge funds have recently bought and sold shares of the stock. Park Avenue Securities LLC increased its holdings in Zimmer Biomet by 158.6% in the third quarter. Park Avenue Securities LLC now owns 5,249 shares of the medical equipment provider’s stock valued at $567,000 after buying an additional 3,219 shares during the last quarter. Czech National Bank increased its holdings in shares of Zimmer Biomet by 5.8% in the 3rd quarter. Czech National Bank now owns 41,486 shares of the medical equipment provider’s stock valued at $4,478,000 after acquiring an additional 2,282 shares during the last quarter. GAMMA Investing LLC raised its position in shares of Zimmer Biomet by 39.0% during the 3rd quarter. GAMMA Investing LLC now owns 1,371 shares of the medical equipment provider’s stock worth $148,000 after acquiring an additional 385 shares in the last quarter. Brookstone Capital Management lifted its stake in Zimmer Biomet by 5.3% during the third quarter. Brookstone Capital Management now owns 6,388 shares of the medical equipment provider’s stock worth $690,000 after purchasing an additional 322 shares during the last quarter. Finally, CWM LLC increased its stake in Zimmer Biomet by 7.4% in the third quarter. CWM LLC now owns 6,966 shares of the medical equipment provider’s stock valued at $752,000 after purchasing an additional 481 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.